GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
–Encouraging preliminary signs of biologic activity and a favorable safety profile are outcomes that are clinically relevant to patients – Enrollment ongoing in additional dose groups, which will include pediatric patients; interim data from these additional dose groups expected in 2H of 2020 –
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 22, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Management and External Thought Leaders to Discuss Data from XLRP and ACHM Phase 1/2 Clinical Trials Webcast Scheduled from 7:30 am – 12:00 pm ET GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology
- Data suggest durable and meaningfully improvements in central visual sensitivity - Secondary data showed encouraging improvements in Best Corrected Visual Acuity - All patients dosed continue to demonstrate a favorable safety profile - Company plans to initiate pivotal trial by the end of 2020 -
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
Company to host R&D Day on January 28, 2020 , in New York GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies
